The present invention relates to a method for preparing commercial scale quantities of canine functional beta cells and to the establishment of cell lines from immature canine pancreatic tissues. It also relates to a method of diagnosis using canine beta cell tumours or cells derived thereof. The method comprises sub-transplantation procedure to enrich the graft in proliferating beta cells, allowing generating canine Beta cell lines. Such lines express, produce and secrete insulin upon glucose stimulation.

A cell-containing structure is provided that allows ready-to-use nerve drug response evaluation with high reproducibility to be easily performed. The cell-containing structure for evaluating an electrical property of neurons includes: (a) a culture surface to which the neurons are able to be adhered; (b) a cell mass that is adhered to the culture surface and contains at least one of the neurons; and (c) a plurality of electrodes for measuring the electrical property of the cell mass, wherein a spontaneous firing frequency of cells contained in the cell mass is 0.25 Hz or more per electrode.

The invention disclosed herein generally relates to methods and systems for converting stem cells into specific tissue(s) or organ(s) through directed differentiation. In particular, the invention disclosed herein relates to methods and systems for promoting human self-organizing single-rosette spheroids (SOSRS), a type of brain organoid, comprising neuroepithelium having either a dorsal cell fate or a ventral cell fate formation from pluripotent stem cells.

This disclosure relates to genetically engineered retinal organoids that can be used to test therapeutic treatments.

A novel tissue usable for a kidney tissue model is provided. A method for producing a kidney-like tissue includes co-culturing a cell group containing mesenchymal stem cells, vascular endothelial cells, and clonal embryonic kidney cells.

An in vitro population of human brain endothelial cells (hBECs) expressing claudin-5, occludin, ZO-1 and GLUT-1 and expressing one or more of FZD7, WNT7A, WNT7B, APCDD1, STRA6 and ZO-3 is provided. A blood brain barrier (BBB) comprising the hBECs and use of the BBB for analyzing permeability characteristics of a test agent are provided.

Compositions for altering splicing activity of the DcpS gene and increasing SMN protein expression in target cells are provided. Also disclosed are methods of use of such compositions for the treatment of SMA.

The disclosure generally relates to methods and compositions for preparing a neural tissue construct. In particular, provided herein are methods for generating a neural tissue construct using glutamatergic cortical progenitor cells; GABAergic interneuron progenitor cells; and bio-ink.

An artificial tissue containing pancreatic islet cells, fibroblasts and/or cells capable of differentiating, extracellular matrix, and vascular endothelial cells, in which the fibroblasts and/or the cells capable of differentiating, the extracellular matrix, and the vascular endothelial cells constitute a three-dimensional tissue structure in which a vascular network structure has been formed, and in which the three-dimensional tissue structure contains pancreatic islets constituted by aggregating ten or more of the pancreatic islet cells.

Described herein are methods, compositions, and assay systems that provide a useful ex vivo model for neurodegenerative disorders, by providing a whole brain organotypic slice culture model maintains viability of mature CNS cells from adult animals. In addition, the whole brain slice cultures described herein exhibit hallmarks of chronic neuroinflammation, where hallmarks are consistent across age-related neurodegenerative disorders. Also provided herein is a cultured whole brain slice which exhibits at least one characteristic of chronic neuroinflammation.